Existing atherosclerotic cardiovascular disease (ASCVD) risk calculators appear to be inadequate, noted researchers led by ...

Current cardiac screening tools used to prevent heart attacks fail to identify nearly half of the people who are actually at ...

PCSK9 inhibitor therapy is less likely to be utilized in Black, Hispanic, and low-income patients hospitalized with ...

Around half of study participants, all age 65 or younger, wouldn’t have been eligible for statins if they’d sought care 2 ...

Population-based age- and sex-specific percentiles for 30-year cardiovascular disease (CVD) risk have been developed based on ...

Current cardiac screening tools used to prevent heart attacks fail to identify nearly half of the people who are actually at risk of having one ...

Released in 2023, PREVENT is a tool estimating CVD, ASCVD, and heart failure risk over 10 or 30 years for adults as young as ...

Scribe Therapeutics highlights data underpinning its comprehensive strategy targeting key lipid drivers of ASCVD at AHA Scientific Sessions 2025 ...

Trials of a new cholesterol-lowering pill have shown promising results for people with heterozygous familial ...

Panel (A) shows classifications based on the ASCVD Risk Estimator Plus, where 45% (209/465) of patients would not have ...

Cholesteryl ester transfer protein inhibition has previously demonstrated significant efficacy in reducing atherogenic lipids and may benefit high-risk patients who are unable to achieve their LDL ...

Statin therapy may attenuate the elevated MACE risk typically observed with tofacitinib vs TNF inhibitors among patients with RA and pre-existing ASCVD.